Abstract
Degarelix is a gonadotropin-releasing hormone (GnRH) blocker with an immediate onset of action that produces fast, profound and sustained suppression of serum testosterone (T) levels, without T surge. International, multicentre, phase II studies were performed to determine the optimal initiation dose (studies 1 and 2) and maintenance dose (study 2) of Degarelix for hormonal therapy of prostate cancer (CaP).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
